Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Shares Issued (2017 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Shares Issued for 15 consecutive years, with -$4.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Shares Issued rose 96.52% year-over-year to -$4.8 million, compared with a TTM value of $133.5 million through Sep 2025, up 2357.09%, and an annual FY2024 reading of $141.0 million, changed N/A over the prior year.
  • Shares Issued was -$4.8 million for Q2 2025 at Catalyst Pharmaceuticals, down from $4.8 million in the prior quarter.
  • Across five years, Shares Issued topped out at $141.0 million in Q1 2024 and bottomed at -$137.4 million in Q2 2024.
  • Average Shares Issued over 5 years is $9.7 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Shares Issued tumbled 165.57% in 2023, then surged 6458.69% in 2024.
  • Year by year, Shares Issued stood at $685000.0 in 2021, then surged by 367.3% to $3.2 million in 2022, then crashed by 165.57% to -$2.1 million in 2023, then soared by 6458.69% to $133.5 million in 2024, then plummeted by 103.59% to -$4.8 million in 2025.
  • Business Quant data shows Shares Issued for CPRX at -$4.8 million in Q2 2025, $4.8 million in Q1 2025, and $133.5 million in Q4 2024.